Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys.

Tawalbeh, Shefa; Samsel, Alison; Gordish-Dressman, Heather; Hathout, Yetrib; Investigators, Cinrg-Dnhs; Dang, Utkarsh J

Tawalbeh, Shefa; Samsel, Alison; Gordish-Dressman, Heather; Hathout, Yetrib; Investigators, Cinrg-Dnhs; Dang, Utkarsh J.

Afiliação

Tawalbeh S; Department of Biomedical Engineering, Binghamton University, Binghamton, NY 13902, USA.
Samsel A; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA.
Gordish-Dressman H; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA.
Hathout Y; Division of Biostatistics, Children's National Hospital, Washington, DC 20010, USA.
Investigators CD; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY 13902, USA.

J Pers Med ; 10(4)2020 Oct 12.

Article em En | MEDLINE | ID: mdl-33053810

Palavras-chave

Duchenne muscular dystrophy; corticosteroids; deflazacort; glucocorticoids; pharmacodynamic biomarkers; prednisone; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Pers Med Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google